viral
safeti
remain
challeng
process
plasmaderiv
product
varieti
pathogen
might
present
start
materi
requir
downstream
process
capabl
broad
viral
reduct
articl
use
wide
panel
virus
assess
viral
removalinactiv
downstream
process
snake
antivenom
immunoglobulin
sai
first
screen
exclud
equin
plasma
crossreact
model
viru
procedur
publish
antivenom
addit
evalu
first
time
virucid
capac
phenol
appli
sai
product
among
step
analyz
process
phenol
addit
effect
one
follow
heat
capryl
acid
pepsin
virus
fulli
inactiv
phenol
treatment
heat
second
effect
step
inactiv
rotaviru
adenoviru
use
therefor
present
sai
downstream
method
costeffect
elimin
virus
extent
requir
safe
product
humankind
suffer
poison
anim
bite
sinc
begin
time
current
snakebit
repres
main
caus
human
envenom
approxim
occurr
death
yearli
occurr
happen
asia
latin
america
especi
africa
snake
antivenom
immunoglobulin
sai
may
prevent
refer
morbid
mortal
correct
antidot
administ
immedi
bite
condit
howev
impractic
region
need
speci
snake
world
health
organ
endors
relev
sai
global
health
includ
model
list
essenti
medicin
biolog
health
product
requir
rigor
qualiti
control
includ
sai
recent
compil
qualiti
paramet
centenari
product
guidelin
product
control
regul
snake
antivenom
immunoglobulin
document
emphas
viral
content
essenti
control
paramet
contamin
sai
may
infect
human
lead
morbid
even
mortal
inde
contamin
humanderiv
immunoglobulin
led
sever
case
human
infect
hepat
c
viru
phenomenon
far
unreport
animalderiv
immunoglobulin
sai
purifi
hyperimmun
plasma
anim
mainli
hors
immun
predetermin
amount
crude
venom
one
snake
speci
ideal
donor
anim
free
viral
pathogen
approach
fail
incomplet
understand
equin
virolog
consequ
lack
vaccin
therefor
compens
flaw
viral
inactiv
becom
essenti
downstream
process
equin
plasma
sai
purif
diminish
viral
load
contamin
plasma
although
process
valid
guarante
full
elimin
research
report
viral
elimin
throughout
sai
purif
none
describ
prior
plasma
select
base
antivir
titer
select
exclud
plasma
sampl
posit
antibodi
model
virus
use
valid
without
select
neutral
antibodi
may
interfer
measur
viru
titer
essenti
paramet
evalu
capabl
viru
removalinactiv
step
alon
whenev
whole
process
fail
complet
viral
inactiv
modif
like
step
might
improv
outcom
preserv
inactiv
virus
costeffect
repres
plausibl
altern
elimin
viral
activ
exampl
sai
formul
commonli
contain
phenol
although
known
virucid
explor
end
sai
product
literatur
address
issu
classifi
select
plasma
donor
hors
instituto
butantan
brazil
accord
antiviru
immunoglobulin
titer
select
assess
viral
safeti
sai
process
develop
instituto
butantan
evalu
efficaci
phenol
virucid
agent
sai
chose
venom
crotalu
durissu
terrificu
south
american
rattlesnak
cascavel
model
immun
choic
random
institut
produc
sever
snake
antivenom
equin
plasma
procedur
type
venom
influenc
outcom
viru
remov
fifteen
healthi
adult
hors
immun
intramuscular
rout
snake
venom
anim
test
equin
infecti
anemia
viru
everi
month
consid
free
viru
anim
also
previous
immun
rabi
equin
influenza
viru
leptospirosi
tetanu
venezuelan
equin
enceph
viru
immun
scheme
produc
antivenom
serum
consist
three
inocul
day
inocul
day
inject
ml
venom
solut
appli
differ
spot
within
lumbar
region
blood
collect
done
jugular
vein
hors
maximum
hors
weight
week
immun
plasma
obtain
graviti
sediment
blood
c
test
sterilitypot
mycoplasma
content
mycoplasma
pcr
elisa
roch
appli
scienc
viru
screen
plasma
isol
blood
cell
return
donor
hors
plasmapheresi
day
venom
mgml
instituto
butantan
brazil
mix
adjuv
montanid
miner
oil
emuls
seppic
brazil
day
venom
mgml
dilut
salin
solut
day
venom
mgml
dilut
salin
solut
virus
chosen
model
viral
inactiv
studi
describ
tabl
replic
virus
test
cytopath
effect
five
differ
cell
line
use
tabl
cell
line
free
mycoplasma
mycoplasma
pcr
elisa
roch
appli
scienc
cell
cultiv
monolay
cell
cultur
flask
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
supplement
fetal
bovin
serumfb
cutlab
brazil
incub
c
co
subcultiv
passag
perform
cell
monolay
reach
confluenc
ratio
cell
detach
sub
cultiv
achiev
addit
trypsin
sigma
aldrich
edta
solut
merck
viru
replic
use
appropri
cell
line
tabl
cell
cultur
perform
describ
item
cell
cultur
monolay
confluenc
infect
viru
multipl
infect
incub
supernat
collect
identif
visual
cytopath
effect
monolay
cell
debri
remov
centrifug
g
remain
supernat
contain
replic
viru
titrat
store
c
freezer
viru
storag
perform
minimum
concentr
log
measur
tcid
achiev
minimum
concentr
storag
canin
distemp
viru
canin
adenoviru
treat
peg
vv
c
follow
centrifug
g
supernat
discharg
pellet
resuspens
dmem
ml
initi
plasma
volum
cell
tcid
test
tabl
cultiv
item
seed
overnight
cell
cultur
plate
plate
per
viru
contain
cell
per
well
tenfold
serial
dilut
viru
sampl
prepar
inocul
well
respect
plate
eight
replic
per
dilut
row
cultur
medium
use
neg
infect
control
infect
plate
incub
h
viru
infect
dmem
fb
co
follow
medium
renew
dmem
fb
new
incub
maximum
cytopath
effect
day
incub
cell
fix
formaldehyd
stain
crystal
violet
infect
well
stain
wherea
well
contain
intact
cell
stain
bluepurpl
viru
experi
averag
three
viru
assay
use
tcid
calcul
spiermankarb
method
sampl
equin
serum
immun
crotalu
durissu
terrificu
screen
eight
differ
virus
tabl
direct
enzymelink
immunosorb
assay
elisa
unless
otherwis
state
incub
perform
c
wash
step
pbstween
incub
viru
strain
plate
cat
corn
coat
viru
solut
lgml
protein
content
dilut
carbon
buffer
ph
incub
overnight
c
follow
h
block
incub
step
gelatin
serum
sampl
serial
dilut
ad
plate
incub
h
serum
igg
detect
rabbit
antihors
igg
conjug
peroxidas
sigma
eua
incub
h
llwell
time
dilut
incub
room
temperatur
perform
substrat
ophenylenediamin
sigma
eua
hydrogen
peroxid
nuclear
brazil
reaction
stop
min
sulfur
acid
n
plate
read
nm
titertechv
r
spectron
serum
sampl
present
optic
densiti
background
dilut
consid
free
antibodi
test
virus
test
sampl
assay
triplic
repeat
confirm
sai
purif
process
develop
instituto
butantan
brazil
obtain
crotal
antivenom
deriv
equin
plasma
process
optim
previous
develop
method
flowchart
figur
describ
process
obtain
concentr
immunoglobulin
solut
step
identifi
potenti
viral
inactiv
highlight
method
test
alreadi
describ
item
routin
batch
produc
concentr
bulk
dilut
filter
steril
packag
cell
tabl
cytotox
cultiv
item
seed
overnight
plate
cell
cultur
cell
per
well
test
sampl
taken
immedi
four
viral
inactiv
step
item
dilut
serial
twofold
cultur
medium
dilut
sampl
load
plate
incub
co
follow
cell
cultur
medium
remov
mtt
bromid
sigma
eua
solut
ad
incub
perform
h
mtt
remov
isopropanol
use
dissolv
mtt
crystal
result
optic
densiti
measur
nm
titertechv
r
spectron
averag
optic
densiti
control
well
receiv
viru
repres
viabil
well
viabil
calcul
base
control
capabl
viral
inactiv
evalu
chosen
step
follow
direct
guidelin
paper
publish
guidelin
also
relat
viral
removalinactiv
valid
although
design
anim
plasma
deriv
purif
process
without
spike
perform
blank
process
figur
conduct
routin
chosen
step
sampl
spike
one
model
viru
step
perform
describ
result
product
evalu
tcid
model
viru
evalu
separ
experi
step
immedi
spike
evalu
step
duplic
sampl
collect
store
c
quantif
initi
tcid
time
final
tcid
test
sampl
store
c
analys
spike
rate
use
run
tcid
nonspik
run
consid
test
blank
viral
log
reduct
factor
lrf
calcul
run
describ
log
reduct
factor
volum
start
materi
concentr
viru
start
materi
initi
tcid
volum
materi
evalu
step
concentr
viru
step
antivir
immunoglobulin
screen
horsederiv
plasma
sampl
order
verifi
viru
elimin
equin
plasma
chose
eight
strain
virus
model
signific
virus
report
infect
hors
item
tabl
screen
plasma
sampl
donor
hors
antivir
immunoglobulin
detect
elisa
screen
show
posit
sampl
consid
posit
sampl
recogn
least
one
model
viru
viral
recognit
independ
type
genet
materi
presenc
envelop
relat
viral
origin
figur
major
sampl
react
bovin
virus
especi
bvdv
follow
canin
virus
cite
virus
gener
infect
hors
result
probabl
arous
crossreact
antibodi
antibodi
crossreact
may
occur
virus
infect
sever
speci
anim
report
broach
subject
bovin
canin
equin
virus
two
plasma
sampl
antibodi
vesicular
stomat
viru
vsv
model
viru
work
commonli
infect
hors
figur
howev
anim
free
vsv
pcr
screen
data
shown
leav
previou
infect
antibodi
crossreact
probabl
caus
posit
research
found
crude
plasma
contain
mixtur
immunoglobulin
crossreact
variou
antigen
support
result
posit
sampl
exclud
inactiv
studi
allow
specif
viral
elimin
step
test
potenc
sai
defin
amount
snake
venom
neutral
ml
plasma
mgml
measur
work
describ
four
neg
sampl
neutral
least
mgml
minimum
potenc
requir
purif
data
shown
pool
sampl
also
surpass
minimum
protein
valu
mgml
constitut
start
materi
valid
studi
process
obtain
purifi
sai
describ
detail
method
section
item
figur
main
step
cite
sequenti
order
ammonium
sulfat
precipit
immunoglobulin
b
pepsin
digest
obtain
f
ab
fragment
c
capryl
acid
precipit
nonimmunoglobulin
protein
heat
treatment
e
ammonium
sulfat
precipit
f
ab
fragment
f
tangenti
filtrat
g
ionexchang
chromatographi
h
tangenti
filtrat
phenol
addit
among
procedur
chose
b
c
viral
inactiv
studi
report
virucid
capabl
ionexchang
chromatographi
g
also
remov
virus
evalu
step
would
requir
sanit
use
batch
thu
perform
sever
purif
process
pool
sampl
one
spike
step
b
c
eight
model
virus
individu
item
spike
concentr
tabl
differ
viru
consequ
replic
yield
obtain
cdv
titer
consist
six
log
requir
concentr
spike
brv
titer
decreas
slightli
six
log
mix
log
tabl
analyz
cell
cytotox
downstream
step
spike
experi
sampl
taken
chosen
step
toxic
dilut
cultur
medium
therefor
use
dilut
cellbas
assay
cytotox
differ
sampl
assur
viral
safeti
spike
experi
initi
viru
titer
six
log
result
undetect
viru
load
howev
process
still
contribut
viral
safeti
reduct
four
six
log
requir
addit
viral
reduct
meet
european
agenc
evalu
medicin
product
emea
requir
contrast
process
step
present
lrf
four
log
gener
inactiv
insuffici
amount
viru
insur
adequ
safeti
calcul
viral
lrf
downstream
step
least
log
tabl
consid
threshold
effect
step
analyz
amount
virus
inactiv
result
lrf
greater
log
effect
log
contribut
viral
safeti
log
ineffect
collect
data
point
heat
treatment
effect
pepsin
capryl
acid
nevertheless
heat
treatment
perform
presenc
residu
capryl
previou
step
may
influenc
lrf
valu
log
lrf
log
log
pepsin
capryl
process
step
respect
depend
virus
involv
phenol
addit
step
result
undetect
viral
load
differ
viru
suscept
pepsin
capryl
acid
heat
treatment
envelop
virus
experi
suscept
virus
ccv
lrf
log
treatment
herpesvirus
gener
present
low
resist
antivir
treatment
wherea
heat
c
min
h
low
ph
might
reduc
ccv
infect
found
report
use
virus
model
viral
inactiv
concern
describ
purif
step
vsv
bvdv
gener
resist
inactiv
envelop
virus
extens
neutral
heat
treatment
inde
observ
lrf
valu
bvdv
vsv
six
log
treat
phenol
heat
six
four
log
treat
pepsin
capryl
acid
tabl
respect
vsv
research
also
found
lrf
rang
pepsin
capryl
acid
treatment
anoth
experi
show
treatment
reduc
approxim
log
vsv
min
follow
consist
inactiv
log
min
latter
find
suggest
inactiv
could
extend
vsv
process
reach
h
instead
min
pepsin
min
capryl
acid
nevertheless
consid
extend
paramet
may
also
diminish
serum
potenc
protocol
achiev
extend
inactiv
heat
step
report
unnecessari
extend
step
might
decreas
activ
kill
specif
viru
concern
bvdv
previou
literatur
show
similar
trend
result
capryl
acid
pepsin
treatment
ph
except
work
report
highbvdv
resist
pepsin
treatment
ph
higher
resist
found
work
might
spike
plasma
contain
bvdv
antibodi
plasma
contain
antibodi
bound
bvdv
initi
titer
may
underestim
decreas
ph
might
destabil
previou
antibodyantigen
bind
releas
infect
virus
detect
begin
consequ
event
underestim
reduct
factor
four
envelop
virus
discuss
inactiv
greater
extent
nonenvelop
virus
known
gener
properti
virus
except
trend
envelop
cdv
present
lrf
phenol
addit
resist
probabl
aros
anim
proteinviru
interact
previou
report
describ
cdv
protect
inactiv
calf
serum
egg
tissu
present
later
find
quit
relev
illustr
virus
easili
inactiv
environ
quit
resist
biolog
fluid
therefor
includ
valid
panel
nonenvelop
virus
resist
viru
detect
experi
poorli
neutral
pepsin
capryl
acid
heat
treatment
tabl
brv
also
poorli
neutral
acid
treatment
ph
min
effect
inactiv
pepsin
capryl
step
lrf
moder
inactiv
heat
step
acid
ph
log
experi
yamamoto
colleagu
inactiv
log
increas
pepsin
concentr
extens
reaction
time
h
howev
increment
caus
loss
activ
discuss
anoth
paper
petr
jiran
complet
inactiv
serumfre
medium
ph
heat
inactiv
increas
sensibl
heat
probabl
result
ph
use
particularli
unstabl
neutral
ph
rang
capryl
pepsin
treatment
gener
consid
unsuit
inactiv
nonenvelop
virus
found
except
establish
trend
nonenvelop
cpv
substanti
inactiv
refer
treatment
log
could
find
paper
use
canin
parvoviru
valid
refer
treatment
crude
plasma
sampl
avoid
perform
comparison
parvovirus
differ
initi
product
high
variabl
found
among
parvoviru
group
nevertheless
cpv
seem
quit
vulner
acid
ph
condit
maintain
pepsin
step
order
guarante
worstcas
scenario
parvoviru
inactiv
one
would
test
differ
parvovirus
condit
test
cpv
phenol
common
preserv
product
deriv
anim
immunoglobulin
efficaci
bacteria
extens
studi
report
approach
phenol
virucid
scarc
literatur
addit
phenol
concentr
bulk
result
inactiv
model
virus
min
exposur
evidenc
undetect
valu
tcid
partial
total
inactiv
expect
cv
vsv
bvdb
cdv
phenol
compound
describ
effici
virucid
agent
envelop
virus
howev
inactiv
phenol
nonenvelop
virus
differ
viru
speci
studi
model
virus
use
work
also
model
human
virus
instanc
bvdv
use
surrog
model
hepat
c
viru
cpv
model
human
parvoviru
virus
import
agent
viral
infect
human
blood
product
consequ
target
viral
inactiv
phenol
inactiv
virus
indic
might
also
effect
preserv
humanderiv
immunoglobulin
come
viral
safeti
concern
phenol
safeti
use
high
concentr
report
facilit
format
igg
aggreg
dimmer
contribut
turbid
solut
c
vivo
effect
mice
includ
transient
hypotens
disturb
leukocyteendotheli
interact
dilut
phenol
report
toxic
destabil
agent
formula
process
describ
util
phenol
concentr
bulk
min
batch
product
dilut
abrog
possibl
report
side
effect
antibodi
crossreact
common
featur
virus
speci
genu
infect
differ
anim
found
sever
evid
viru
inactiv
thu
possibl
crossreact
show
first
time
equin
plasma
recogn
wide
array
typic
model
virus
includ
substanti
amount
bvdv
viru
commonli
belong
valid
panel
especi
hcv
model
viral
screen
becom
essenti
evalu
virucid
step
concern
perform
step
phenol
effect
one
follow
heat
capril
acid
pepsin
expect
result
phenol
heat
treatment
dedic
elimin
microb
ideal
phenol
use
complement
bactericid
purpos
virucid
properti
quit
import
resist
nonenvelop
virus
poorli
inactiv
treatment
present
case
protocol
phenol
abl
inactiv
virus
phenol
compound
addit
report
virucid
equin
infecti
anemia
viru
essenti
featur
donor
hors
locat
endem
region
envelop
viru
process
might
remov
resist
virus
like
nanofiltr
product
cost
surpass
budget
region
need
therefor
present
sai
purif
method
costeffect
elimin
virus
extent
requir
safe
product
addit
process
may
appli
equinederiv
immunoglobulin
like
spider
scorpion
antivenom
rabi
immunoglobulin
product
variabl
antigen
obtent
hors
immun
scheme
happen
plasma
collect
therefor
interfer
downstream
process
